Summary
Spero Therapeutics: 'Buy' On Utebzi Royalty Deal For Funding And SP001 In-Licensing
Spero Therapeutics is initiated with a "Buy" rating, driven by its strategic pivot to immunology and strong non-dilutive financing. SPRO secured FDA approval for Utebzi and a $105M royalty deal, enabling funding for SP001 development without shareholder dilution. SP001, a third-generation anti-CD40L antibody, targets IgG4-RD and Sjögren's disease, with phase 2 trials planned for 2027 and a differentiated, B-cell-sparing MOA.
Down 17.7% in 4 Weeks, Here's Why Spero Therapeutics (SPRO) Looks Ripe for a Turnaround
The heavy selling pressure might have exhausted for Spero Therapeutics (SPRO) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Spero Therapeutics, Inc. (SPRO) Q2 2025 Earnings Call Transcript
Spero Therapeutics, Inc. (NASDAQ:SPRO ) Q2 2025 Earnings Conference Call August 12, 2025 4:30 PM ET Company Participants Esther P. Rajavelu - CEO, CFO, President & Treasurer Shai Biran - Corporate Participant Timothy Keutzer - Chief Operating Officer Conference Call Participants Gautam Chukka - Evercore ISI Institutional Equities, Research Division Operator Good afternoon, and welcome to Spero Therapeutics Second Quarter 202 Earnings Conference Call.
Spero Therapeutics Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 Point72 Asset Management LP Point72 Asset Management LP | 59,668 | $139,187.23 | $99,943.9 | -$39,243.33 | -28.19% |
 Michael Byun SageView Advisory Group LLC | 17 | $40 | $27.98 | -$12.02 | -30.05% |
| HFT Hui Fai Tam Caitong International Asset Management Co. Ltd. | 3 | $7 | $4.89 | -$2.11 | -30.14% |
 Christopher C. Powers Farther Finance Advisors, LLC | 10 | $23 | $15.8 | -$7.2 | -31.3% |
 Carmen McClennon WR Wealth Planners, LLC | 2,600 | $4,472 | $4,030 | -$442 | -9.88% |
Spero Therapeutics Inc. (SPRO) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Spero Therapeutics Inc. ever had a stock split?
Spero Therapeutics Inc. Profile
| Biotechnology Industry | Healthcare Sector | Esther Rajavelu CEO | NASDAQ (NGS) Exchange | 84833T103 CUSIP |
| US Country | 25 Employees | - Last Dividend | - Last Split | 2 Nov 2017 IPO Date |
Overview
Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company that specializes in the development and commercialization of innovative treatments targeting multi-drug resistant (MDR) bacterial infections and rare diseases within the United States. Founded in 2013, the company is committed to addressing the growing challenge of antibiotic resistance through its focused research and development efforts. With its headquarters in Cambridge, Massachusetts, Spero Therapeutics stands at the forefront of combating infections that are increasingly resistant to existing antibiotic treatments, aligning its mission with a critical global health need.
Products and Services
The company's pipeline consists of promising candidates that include:
- Tebipenem Pivoxil Hydrobromide (HBr): This oral carbapenem-class antibiotic is being developed for the treatment of complicated urinary tract infections (cUTIs), including pyelonephritis, in adults. As the first oral drug in its class, tebipenem HBr represents a significant advancement in the treatment of these infections, potentially providing an effective alternative to intravenous (IV) antibiotics.
- SPR206: This IV-administered antibiotic is designed to combat MDR Gram-negative pathogens, such as carbapenem-resistant enterobacterales (CRE), acinetobacter baumannii, and pseudomonas aeruginosa. Its development focuses on addressing severe bacterial infections within hospital settings, where resistance to existing antibiotics is most prevalent.
- SPR720: An innovative oral antibiotic agent aimed at treating non-tuberculous mycobacterial (NTM) pulmonary disease. This stands as a novel approach to tackling a growing health concern, offering hope to patients suffering from these chronic, debilitating infections that are difficult to treat with current medications.
In support of developing these significant product candidates, Spero Therapeutics has entered into strategic licensing agreements with several industry players. These partnerships include an agreement with Meiji Seika Pharma Co., Ltd. for the development of tebipenem HBr; Everest Medicines to oversee the development, manufacturing, and commercialization of SPR206 across Greater China, South Korea, and Southeast Asia; and an agreement with Vertex Pharmaceuticals Incorporated covering patents related to SPR720 and its active metabolite, SPR719.
